In our analysis of the DAPA-LVH trial, we found that in patients with T2D and LVH dapagliflozin significantly reduced CRP but did not cause statistically significant changes in inflammatory cytokines, eosinophils, neutrophils, ELR, and NLR. Here, CRP is linked to type 2 diabetes mellitus.